Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Stilla Technologies currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, indicating a singular point of contact within the patent office for the company's current filings. The prosecution is localized within 1 distinct art unit, which focuses the technical review process on a specific area of biotechnology. This concentration allows the company to dedicate its resources to addressing the specific concerns of 1 distinct examiner, rather than managing a diverse array of office actions.
The busiest examiner identified is VANN-OJUEKAIYE, KENDRA RAYCHELL, who is handling 1 busiest examiner pending action. Since this is the 1 busiest examiner pending action for the company, this examiner's specific approach to biotechnology claims will be the determining factor for the portfolio's immediate progress. The limited scope of 1 pending office action suggests a focused prosecution effort. By interacting with 1 distinct examiner, the company can better predict potential hurdles based on that individual's past examination history. This focused approach within 1 distinct art unit ensures that the company's legal strategy is aligned with the technical expectations of the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17918316 | METHOD FOR DETECTING GENETIC EVENTS | VANN-OJUEKAIYE, KENDRA RAYCHELL | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17918316 | METHOD FOR DETECTING GENETIC EVENTS | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103 | Non-Final OA | — | Pending | Oct 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStilla Technologies has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kendra Raychell Vann-Ojuekaiye has the most, with 1 of Stilla Technologies's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
